X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse AMAR REMEDIES with THE PROCTER & GAMBLE CO. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES vs P&G (US) - Comparison Results

P&G (US)
   Change

Procter & Gamble Company (P&G) is an American multinational consumer goods company headquartered in the United States. The company was incorporated in Ohio in 1905, having been built from a business founded in 1837 by William Procter and James Gamble... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AMAR REMEDIES   P&G
EQUITY SHARE DATA
    AMAR REMEDIES
Jun-12
P&G
Jun-14
AMAR REMEDIES/
P&G
5-Yr Chart
Click to enlarge
High Rs1645,569-   
Low Rs864,777-   
Sales per share (Unadj.) Rs261.61,961.4-  
Earnings per share (Unadj.) Rs17.4274.9-  
Cash flow per share (Unadj.) Rs22.3349.1-  
Dividends per share (Unadj.) Rs0158.98-  
Dividend yield (eoy) %03.1 0.0%  
Book value per share (Unadj.) Rs100.71,634.4-  
Shares outstanding (eoy) m26.162,748.03-   
Bonus/Rights/Conversions -BB, ESOP-  
Price / Sales ratio x0.52.6 18.1%   
Avg P/E ratio x7.218.8 38.2%  
P/CF ratio (eoy) x5.614.8 37.9%  
Price / Book Value ratio x1.23.2 39.2%  
Dividend payout %057.8 0.0%   
Avg Mkt Cap Rs m3,27014,214,752 0.0%   
No. of employees `000NA118.0 0.0%   
Total wages/salary Rs m1630-   
Avg. sales/employee Rs ThNM45,677.1-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM6,402.7-  
INCOME DATA
Net Sales Rs m6,8445,389,893 0.1%  
Other income Rs m2119,856 0.1%   
Total revenues Rs m6,8655,409,750 0.1%   
Gross profit Rs m1,1311,200,919 0.1%  
Depreciation Rs m128203,819 0.1%   
Interest Rs m39846,007 0.9%   
Profit before tax Rs m626970,949 0.1%   
Minority Interest Rs m0-9,214 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-500-   
Tax Rs m121206,220 0.1%   
Profit after tax Rs m455755,514 0.1%  
Gross profit margin %16.522.3 74.2%  
Effective tax rate %19.321.2 91.0%   
Net profit margin %6.614.0 47.4%  
BALANCE SHEET DATA
Current assets Rs m4,9042,051,627 0.2%   
Current liabilities Rs m3,5812,188,480 0.2%   
Net working cap to sales %19.3-2.5 -761.3%  
Current ratio x1.40.9 146.1%  
Inventory Days Days12430 418.4%  
Debtors Days Days10028 356.9%  
Net fixed assets Rs m1,6891,447,307 0.1%   
Share capital Rs m262332,237 0.1%   
"Free" reserves Rs m2,3580-   
Net worth Rs m2,6354,491,296 0.1%   
Long term debt Rs m5071,285,536 0.0%   
Total assets Rs m6,8629,290,561 0.1%  
Interest coverage x2.622.1 11.6%   
Debt to equity ratio x0.20.3 67.2%  
Sales to assets ratio x1.00.6 171.9%   
Return on assets %12.48.6 144.1%  
Return on equity %17.316.8 102.7%  
Return on capital %31.017.4 177.7%  
Exports to sales %4.00-   
Imports to sales %00-   
Net fx Rs m2710-   
CASH FLOW
From Operations Rs m-313905,735 -0.0%  
From Investments Rs m-489-266,503 0.2%  
From Financial Activity Rs m769-472,334 -0.2%  
Net Cashflow Rs m-33166,897 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for P&G (US) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare AMAR REMEDIES With: UNILEVER PLC. (UK)  HYPERMARCAS (Brazil)  

Compare AMAR REMEDIES With: K.S.OILS LTD  BAJAJ CORP  P&G HYGIENE  LINC PEN & PLASTICS LTD  RELAXO FOOTWEARS  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AMAR REMEDIES 8-QTR ANALYSIS

COMPARE AMAR REMEDIES WITH

MARKET STATS